Infertility Drugs Market - By Drug Class (Gonadotropins, Aromatase Inhibitors), Route of Administration (Parenteral, Oral), Gender (Female, Male), Distribution Channel (Hospital Pharmacies, Specialty & Retail Pharmacy) & Forecast 2023 - 2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationInfertility Drugs Market - By Drug Class (Gonadotropins, Aromatase Inhibitors), Route of Administration (Parenteral, Oral), Gender (Female, Male), Distribution Channel (Hospital Pharmacies, Specialty & Retail Pharmacy) & Forecast 2023 - 2032
Infertility Drugs Market Size
Infertility Drugs Market size accounted for USD 3.6 billion in 2022 and is estimated to grow at 5.9% to reach USD 6.4 billion by 2032. Governments across the globe are launching number of programmes to help people with infertility problems by offering insurance coverage for therapy.
For instance, from April 2022 onwards, Japan’s public health insurance will reimburse fertility treatments, with an aim to make the treatments more accessible to patients by effectively lowering the cost by 70%. Such initiatives will accelerate the market progress. Furthermore, it is also anticipated that the availability of a wide range of medications for the treatment of infertility issues will benefit the industry.
Infertility drugs are a pharmaceutical product specifically designed to address and treat infertility-related issues in individuals or couples. These drugs are formulated to regulate hormone levels, stimulate ovulation, improve sperm production or quality, enhance the chances of successful fertilization, or address underlying medical conditions that contribute to infertility.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Infertility Drugs Market Size in 2022 | USD 3.6 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 5.9% |
| 2032 Value Projection | USD 6.4 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 180 |
| Tables, Charts & Figures | 269 |
| Segments covered | Drug Class, Route of Administration, Gender, Distribution Channel and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic had negatively affected the infertility drugs market. The pandemic led to delays in infertility diagnoses and treatments, as healthcare resources were redirected to address COVID-19 patients. This delay in care has potentially impacted the demand for infertility drugs. For instance, in March 2020, the American Society for Reproductive Medicine (ASRM) issued guidelines to stop all new fertility treatment cycles and non-urgent diagnostic procedures.
Also, during this time, a study by Strata Decision Technology in 228 hospitals across 40 states in U.S. found patient encounters for infertility services were down 83% from March 22 to April 4, 2020, as compared to the previous year. Moreover, disruptions in global supply chains due to lockdowns, travel restrictions, and temporary closures of manufacturing facilities had created challenges in the availability and distribution of infertility drugs. Thus, decreased patient number along with aforementioned factors had negatively impacted the market growth in 2020.
Infertility Drugs Market Trends
Infertility has become a growing concern around the world. Did you know that roughly one out of every six adults, or around 17.5% of the population, struggles with it? This means there's a huge need for affordable and reliable fertility treatments. Why is infertility on the rise? Well, it's a combination of things. People are having children later in life, and lifestyle choices can also play a role. Health conditions like polycystic ovary syndrome (PCOS) and endometriosis can make it harder to conceive too. As the world's population ages and birth rates fall, the demand for fertility treatments is only going to grow. So, it's no wonder that the market for fertility treatments and drugs is expected to keep expanding in the years to come.
Infertility Drugs Market Restraint
Infertility drugs can be a double-edged sword. They give couples hope of having a baby, but they also come with a list of potential side effects. Headaches, mood swings, and bloating are just the tip of the iceberg. Some women experience more serious problems like OHSS (Ovarian Hyperstimulation Syndrome). OHSS can make your ovaries swell and fill your body with fluid. This can lead to belly pain, trouble breathing, and even life-threatening complications in rare cases. These side effects can put a big damper on the market for infertility drugs. People want to have babies, but they don't want to risk their health to do it. So, it's a tough balancing act for drug companies to make effective drugs that don't cause too many problems.
Infertility Drugs Market Analysis
By drug class, the infertility drugs market is classified into gonadotropins, aromatase inhibitors, selective estrogen receptor modulators (serms), dopamine agonists, and other drug classes. The gonadotropins segment accounted for 41.5% of the market share in 2022 and is projected to witness robust growth over the analysis timeframe. Growing demand for assisted reproductive technologies (ART) such as in-vitro fertilization (IVF) services and intrauterine insemination (IUI), where gonadotrophins play a crucial role will supplement the segment share. Moreover, advancements in technology and research are leading to the development of more refined and targeted gonadotrophin formulations.
Based on route of administration, the infertility drugs market is segmented into parenteral, oral, and topical. The parenteral route of administration is expected to register around USD 3.6 billion by 2032. The parenteral route includes injections and intravenous infusion, which offers direct and rapid delivery of infertility drugs into the bloodstream. This ensures more efficient and predictable absorption of the drugs, resulting in faster onset of action and improved treatment outcomes. Therefore, healthcare professionals and patients are increasingly opting for parenteral administration for infertility drugs, thereby propelling market trends. Moreover, the parenteral route of administration allows for precise dosing and individualized treatment regimens, thereby augmenting the market size.
When it comes to infertility, there are two main groupspeople who identify as female and people who identify as male. In 2022, most of the money spent on infertility drugs was on treatments for women. And this is expected to keep growing by 6.1% over the next few years. One of the biggest reasons for this growth is that more and more women are struggling to get pregnant. For example, in the United States, about 1 in 5 married women between the ages of 15 and 49 who haven't had any children yet have trouble getting pregnant after trying for a year. And about 1 in 4 women in this group have trouble getting pregnant or carrying a pregnancy to term (having a baby). So, as more women have trouble getting pregnant, the market for infertility drugs for women is likely to keep growing. Also, more and more women are being diagnosed with Polycystic Ovary Syndrome (PCOS), which can also make it harder to get pregnant. So, this is another reason why the market for infertility drugs for women is expected to grow.
In the market for infertility drugs, there are three main ways to get themthrough hospital pharmacies, specialty and retail pharmacies, or online pharmacies. In 2022, hospital pharmacies raked in a whopping $2 billion. Why? More and more people are struggling with infertility, and they're also getting more informed about it. This means there's a growing need for specialized meds to help them conceive. Hospital pharmacies have got a huge selection of these drugs, so they're in a prime position to meet this demand. Plus, they have the best infrastructure and know-how to make sure these treatments are tailored to each patient's individual needs. That's why hospital pharmacies are the go-to spot for infertility drugs, and their business is only going to keep growing.
Hey there! You've probably heard about the growing infertility drug market in North America, right? Well, it's a big deal, taking up over 40% of the market in 2022. And guess what? It's only going to keep getting bigger over the next few years. One reason for this growth is that more and more people are choosing to live inactive lifestyles. This is true for both women and men. And this lazy lifestyle isn't doing us any favors. It can lead to hormonal imbalances, weight problems, and even a condition called polycystic ovarian disease. These can all make it harder for people to have babies. So, there you have it. The rise of the infertility drug market is partly due to our increasingly inactive lifestyles. If you're looking to start a family, it might be time to rethink your couch-potato ways and get moving!
Therefore, growing adoption of sedentary lifestyle will foster the market outlook. Further, the market for infertility drugs in the region is expanding because of several factors including a high concentration of market players, mergers and collaborations among significant players, and an increase in the number of infertility and PCOS cases.
Infertility Drugs Market Share
Major market players operating in the infertility drugs market include
- Merck KGaA
- Ferring B.V.
- Abbott
- Livzon
- Pfizer Inc.
- Mankind Pharma
- Teva Pharmaceutical Industries Ltd.
- IBSA Institut Biochimique SA
These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Infertility Drugs Industry News
- In August 2021, Merck Specialties Pvt ltd, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India. The Pergoveris Pen provide combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. This strategy helped the company to enhance its product offering in market and assist in strengthening the market position.
- In December 2019, Mankind Pharma launched its generic Dydrogesterone tablets for treatment of infertility and pregnancy related complications in the Indian market. The company’s product is generic version of Abbott’s Duphaston tablets. This strategy helped the company to expand and grow.
The infertility drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Other drug classes
Route of Administration
- Oral
- Parenteral
- Topical
Gender
- Female
- Male
Distribution Channel
- Hospital Pharmacies
- Specialty & Retail Pharmacies
- Online Pharmacies
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy